BDBM326300 4-{[(1R)-1- cyclobutylethyl] amino}-6-(3- methylphenyl)-5-[4- (trifluoromethoxy) benzyl]-5H-pyrrolo[3,2- d]pyrimidine-2- carboxylic acid::US9637493, 2.3
SMILES: C[C@@H](Nc1nc(nc2cc(-c3cccc(C)c3)n(Cc3ccc(OC(F)(F)F)cc3)c12)C(O)=O)C1CCC1
InChI Key: InChIKey=KUHCGKHPBZJDBH-QGZVFWFLSA-N
Data: 1 IC50
Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kcal/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
p53-binding protein Mdm2 (Homo sapiens (Human)) | BDBM326300 (4-{[(1R)-1- cyclobutylethyl] amino}-6-(3- methylph...) | PDB GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 348 | n/a | n/a | n/a | n/a | n/a | n/a |
Merck Sharp & Dohme Corp. US Patent | Assay Description Methods: An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM... | US Patent US9637493 (2017) BindingDB Entry DOI: 10.7270/Q28917Z1 | |||||||||||
More data for this Ligand-Target Pair |